Financial overview
Five-year overview summary
Always refer to the electronic version of the ASML Annual Reports based on US GAAP for the full and official financial information.
| Income statement Year ended December 31 (€, in millions, except per share data) | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | 11, 820.0 | 13,978.5 | 18,611.0 | 21,173.4 | 27,558.5 |
| Gross profit | 5,279.8 | 6,797.2 | 9,809.0 | 10,700.1 | 14,136.1 |
| Research and development costs | (1,968.5) | (2,200.8) | (2,547.0) | (3,253.5) | (3,980.6) |
| Selling, general and administrative costs | (520.5) | (544.9) | (725.6) | (945.9) | (1,113.2) |
| Other income | - | - | 213.7 | - | - |
| Income from operations | 2,790.8 | 4,051.5 | 6,750.1 | 6,500.7 | 9,042.3 |
| Net income | 2,592.3 | 3,553.7 | 5,883.2 | 5,624.2 | 7,839.0 |
| Gross profit as a percentage of net sales | 44.7% | 48.6% | 52.7% | 50.5% | 51.3% |
| Income from operations as a percentage of net sales | 23.6% | 29.0% | 36.3% | 30.7% | 32.8% |
| Basic net income per share | 6.16 | 8.49 | 14.36 | 14.14 | 19.91 |
| Diluted net income per share | 6.15 | 8.48 | 14.34 | 14.13 | 19.89 |
| Number of ordinary shares used in computing per share amounts: | |||||
| Basic | 420.8 | 418.3 | 409.8 | 397.7 | 393.8 |
| Diluted | 421.6 | 419.1 | 410.4 | 398.0 | 394.1 |
| Balance sheet as of December 31 (€, in millions) |
2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 3,532.3 | 6,049.4 | 6,951.8 | 7,268.3 | 7,004.7 |
| Short-term investments | 1,185.8 | 1,302.2 | 638.5 | 107.7 | 5.4 |
| Total assets | 22,629.6 | 27,267.4 | 30,231.0 | 36,300.4 | 39,957.5 |
| Long-term debt (current and non – current) | 3,108.3 | 4,678.2 | 4,584.1 | 4,260.4 | 4,631.6 |
| Shareholders' equity | 12,592.2 | 13,865.4 | 10,140.6 | 8,810.8 | 13,452.4 |
| Employees as of December 31 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Number of payroll employees (in FTEs) | 23,219 | 26,614 | 29,861 | 36,112 | 40,309 |
